ANI Pharmaceuticals, Inc. (ANIP) Issues Quarterly Earnings Results
ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) announced its quarterly earnings data on Wednesday. The specialty pharmaceutical company reported $1.11 EPS for the quarter, topping the consensus estimate of $0.99 by $0.12, Bloomberg Earnings reports. The business had revenue of $48.16 million for the quarter, compared to analyst estimates of $48.12 million. ANI Pharmaceuticals had a net margin of 3.35% and a return on equity of 22.70%. The company’s revenue for the quarter was up 25.0% on a year-over-year basis. During the same quarter in the previous year, the firm posted $1.09 earnings per share.
ANIP has been the topic of several research reports. Canaccord Genuity initiated coverage on shares of ANI Pharmaceuticals in a research report on Monday, July 31st. They issued a “buy” rating and a $60.00 price objective on the stock. Zacks Investment Research upgraded shares of ANI Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Wednesday, July 5th. Finally, BidaskClub upgraded shares of ANI Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Friday, August 18th. Four equities research analysts have rated the stock with a hold rating and two have given a buy rating to the company’s stock. ANI Pharmaceuticals presently has a consensus rating of “Hold” and an average target price of $67.33.
ILLEGAL ACTIVITY NOTICE: “ANI Pharmaceuticals, Inc. (ANIP) Issues Quarterly Earnings Results” was originally reported by American Banking News and is the property of of American Banking News. If you are reading this article on another website, it was copied illegally and republished in violation of U.S. and international copyright legislation. The original version of this article can be accessed at https://www.americanbankingnews.com/2017/11/02/ani-pharmaceuticals-inc-anip-issues-quarterly-earnings-results.html.
ANI Pharmaceuticals Company Profile
ANI Pharmaceuticals, Inc is an integrated specialty pharmaceutical company. The Company is engaged in developing, manufacturing and marketing branded and generic prescription pharmaceuticals. The Company focuses on areas, including controlled substances, anti-cancer (oncolytics), hormones and steroids, and complex formulations.
Receive News & Ratings for ANI Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ANI Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.